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rug-Eluting Stents
ife Insurance With
Better Death Benefit*
. Vernon Anderson, MD, FACC, FSCAI
ouston, Texas
he phrase “off-label use” has been much overused, often in
negative sense. This is unfortunate. It is especially unfor-
unate in the case of drug-eluting stents, which are one of
he greatest achievements of cardiovascular medicine. Clin-
cal trials used for the approval of drug-eluting stents have
een necessarily restricted to clearly defined subsets of a
uch larger population of diseased patients. Label indica-
ions, if they are strictly derived only from these clinical
rials, will then inevitably be a small and imperfect reflection
f a larger reality.
See pages 2011 and 2017
On the other hand, practitioners of evidence-based med-
cine recognize that randomized clinical trials are only a part
f the “evidence base” regarding any clinical topic. As the
vidence base grows, then recommendations and practices
hange. It was never to be expected that use of coronary
tents would always conform to so-called “label indications.”
linical medicine doesn’t work that way and never has. The
mportant issue is whether the clinical community contin-
ously reevaluates the disease entity with all its treatment
ptions and outcomes. And this the cardiology community
oes zealously and extremely well. In this issue of the
ournal, there are 2 new reports (1,2) adding to the substan-
ial evidence base regarding the safety and efficacy of
rug-eluting stents. Both reports are timely and noteworthy.
omplex coronary disease. Inasmuch as drug-eluting
tents were approved based upon clinical trials involving
elatively “simple” coronary lesions, anything other than a
imple lesion is supposedly off-label. Unfortunately, clini-
ians are confronted every day with complex coronary
isease, and it has been estimated that somewhat more than
ne-half of all stents, both bare-metal as well as drug-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiology Division, University of Texas Health Science Center
ouston, Houston, Texas. Dr. Anderson has received honoraria as a speaker and asP
consultant for Sanofi-Aventis, Bristol-Myers Squibb, and PDL BioPharma. He has
o financial relationships with any stent or any other medical device manufacturer.luting, are implanted for coronary lesions that do not
onform to the label indications for either one (3–8). The
utcomes of intervention in patients with complex lesions
re not as good as the outcomes in simple ones. This is no
urprise.
Kelbæk et al. (9) with the SCANDSTENT (Stenting
oronary Arteries in Non-Stress/Benestent Disease) col-
aborative group have conducted an important randomized
rial that has helped with the complex lesion issue. The
riginal SCANDSTENT report contained angiographic
esults at 6 months and clinical outcomes at 7 months in 322
atients treated with either drug-eluting stents or bare-
etal stents for complex lesions. The SCANDSTENT trial
as similar to 3 other randomized clinical trials that focused
n complex lesions (10–12). Outcomes in all 4 trials were
eported at 7 to 9 months and were quite similar, consis-
ently revealing short-term superiority for drug-eluting
tents. One major difference was that, in SCANDSTENT,
he 4 subsets of “complex” (off-label) lesions were clearly
numerated. In descending order of frequency these were:
hronic total occlusions, bifurcation lesions, ostial lesions,
nd angulated lesions.
The SCANDSTENT group has published separately
heir analyses of both of the first 2 (the largest) of these
ubgroups (13,14). For both chronic occlusions and bifur-
ation lesions, the SCANDSTENT results have contrib-
ted important findings that are consistent with other
ontemporary data. For example, in the 127 patients in
CANDSTENT with chronic occlusions, the binary reste-
osis rates were 0% for drug-eluting stents and 38% for
are-metal stents. In the 200 patients in the PRISON
Primary Stenting of Totally Occluded Native Coronary
rteries) II randomized trial (15), the binary restenosis rates
ere 7% and 36%, respectively. Similar consistency was
ound in the results for bifurcation lesions (16,17).
The new SCANDSTENT report (1) extends the original
ollow-up to 3 years. Overall, the Kaplan-Meier estimates of
vent-free survival at 7 months in the initial report were
5.7% for drug-eluting stents and 70.1% for bare-metal
tents, and these estimates declined slightly but steadily in
arallel to 87.7% and 62.4%, respectively, at 3 years. The
urability of the results is important and gratifying. Inter-
stingly, the occurrence of stent thrombosis according to
cademic Research Consortium definitions at 3 years in
CANDSTENT was lower in the drug-eluting stent group
ompared with the bare-metal stent group (3.1% vs. 4.4%),
hich is similar to the findings in the RAVEL (Random-
zed Comparison of a Sirolimus-Eluting Stent With a
tandard Stent for Coronary Revascularization) trial at 5
ears (3.3% vs 6.8%) (18), although neither difference was
ignificant because of the small numbers of events.
lderly patients. After its introduction in 1977, coronary
alloon angioplasty was applied in all age groups. Its success
n elderly patients was not as great as in younger ones (19).
rocedural complication rates and in-hospital and short-
t
n
s
d
m
i
l
r
c
w
t
e
e
m
i
h
T
r
a
T
i
w
p
n
r
w
p
2
b
m
c
s
p
d
c
p
c
p
c
y
r
p
t
n
a
a
r
t
s
r
l
p
r
y
r
s
r
c
w
w
l
w
d
r
b
s
p
I
r
g
v
o
c
C
p
d
p
a
m
a
i
R
l
F
f
(
m
d
0
m
b
I
b
C
d
n
b
T
c
a
t
a
m
t
2026 Anderson JACC Vol. 51, No. 21, 2008
Editorial Comment May 27, 2008:2025–7erm mortality were greater in the elderly. Many studies
oted that these greater complication rates and lower
uccess rates were associated with the greater burden of
iseases generally found in older people, including more
ultivessel coronary disease, higher incidence of previous
nfarctions, worse left ventricular function, more calcified
esions, and greater numbers of comorbid conditions such as
enal impairment and lung disease. The elderly, then,
onstitute a higher risk group, which helps explain in part
hy elderly patients have been underrepresented in clinical
rials. The perception by physicians of greater risk in the
lderly also helps explain, but does not excuse, the fact that
lderly patients in general do not always receive recom-
ended therapies according to guidelines (20).
For coronary interventions, the situation began to change
n the mid-1990s when bare-metal coronary stents began to
ave an impact in reducing acute complication rates (21).
he elderly benefited from this too, but the anticoagulation
egimens used with coronary stenting in that early era were
ssociated with much greater rates of bleeding in the elderly.
he development of the modern dual-antiplatelet regimens
n place of warfarin, smaller catheters and sheaths, and
eight-based heparin dosing finally reduced bleeding com-
lications in elderly patients to levels at which substantial
et benefits could be realized. A signal publication in this
egard was from a French Registry on stenting without
arfarin, which reported favorable 30-day outcomes in
atients 75 years old (22).
By the time that drug-eluting stents were introduced in
003, it had become established that elderly patients could
enefit from coronary stenting (bare-metal), including even
ultivessel coronary stenting, even though their in-hospital
omplication rates and short- and long-term mortality rates
till remained slightly greater than those found in younger
atients (23–25). At about that same time, it was also
iscovered, somewhat surprisingly, that long-term out-
omes of elderly patients with chronic angina were im-
roved with an early invasive approach that included revas-
ularization (26).
Once the acute complications issues were overcome, the
roblem with bare-metal stenting in the elderly then be-
ame the same problem as that found with stenting in
ounger patients: restenosis. Clark et al. (27) analyzed a
andom sample of Medicare patient data from 1998 (9,868
atients, 28% with acute MI, 80% received stents). From
hese data, they calculated that elderly patients had reste-
osis rates of approximately 15% after coronary intervention
nd that elderly patients, along with the Medicare system as
whole, stood to gain substantially by treatments that could
educe this restenosis rate. Almost simultaneously with this,
he very first report appeared on the use of drug-eluting
tents in octogenarians, revealing a repeat revascularization
ate of 4.2% at 1 year (28).
In this issue of the Journal, Groeneveld et al. (2) report a
ong-term mortality benefit with drug-eluting stents com-
ared with bare-metal stents in elderly patients. In previous leports from randomized trials, including follow-up to 4
ears, the only significant difference to emerge was in repeat
evascularization procedures (due to reduction in resteno-
is), whereas neither death nor myocardial infarctions were
educed (29,30). Nevertheless, the randomized trials in-
luded mostly the simpler, “lower-risk” coronary patients,
ith average ages in the 50s and 60s, for which the trials
ere designed to get clear answers on restenosis. When
arger registries of actual clinical practice are examined,
here there are substantial amounts of complex coronary
isease and complex patients that are beyond the reach of
andomized trials, then a mortality benefit “signal” may
egin to be detected.
Tu et al. (31) in Ontario, Canada, used a propensity
core-matching technique with elimination of unmatched
atients, similar to that performed by Groeneveld et al.
n 7,500 patients with 3 years’ follow-up, the mortality
ate was significantly lower in the drug-eluting stent
roup compared with the bare-metal stent group (5.5%
s. 7.8%, p  0.001). The absolute difference in mortality
f 2% to 3% was similar to the difference in the elderly
ohorts of Groeneveld et al. (2).
On the other hand, the authors of SCAAR (Swedish
oronary Angiography and Angioplasty Registry) (19,000
atients) (32) and the REAL (Registro Angioplastiche
ell’Emilia Romagna) Multicenter Registry in Italy (10,000
atients) (33) did not find mortality differences at 3 years
nd 2 years, respectively, although the propensity score
atching techniques were different in these last 2 studies
nd might have permitted poorly matched outliers to be
ncluded.
The National Heart, Lung, and Blood Institute Dynamic
egistry recently reported an analysis of on-label versus off-
abel use of both drug-eluting as well as bare-metal stents (8).
or off-label use, the unadjusted 1-year mortality was lower
or drug-eluting stents compared with bare-metal stents
3.7% vs. 6.4%, p  0.001). After multivariate risk adjust-
ent, but without propensity score matching, the mortality
ifference was no longer significant (adjusted hazard ratio
.94, 95% confidence interval 0.64 to 1.38). Even so, for
ost of the off-label subgroups examined (e.g., total occlusions,
ifurcation lesions), the National Heart, Lung, and Blood
nstitute analysis indicated superiority for drug-eluting stents,
ased upon reductions in repeat revascularizations.
onclusions. Drug-eluting coronary stents were intro-
uced into clinical practice 5 years ago as a way to inhibit
eointimal hyperplasia and reduce recurrences above and
eyond what could be achieved with bare-metal stents.
hey have succeeded at this mission, both in the simple
oronary lesions in which they were originally tested, as well
s in the more complex lesions and more complex patients
hat constitute the greater bulk of clinical practice. In
ddition to reducing restenosis, it now seems possible that a
ortality benefit is beginning to be signaled. The fact that
his signal is emerging from the more complex (i.e., “off-
abel”) sets of coronary lesions and from elderly patients is
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May 27, 2008:2025–7 Editorial Commenteliciously ironic. Whether these findings will withstand
dditional intense scrutiny and be confirmed with future
nalyses still remains to be seen. If they do stand up, then it
ill be a huge advance. We will still need an explanation of
ow the reduction in neointimal hyperplasia can translate
nto a reduction in fatal events, especially within the brief
eriod of 1 year as suggested by the Groeneveld et al.
nalysis (2). Meanwhile, in the everyday world of clinical
ractice, whenever coronary stents are required for revascu-
arization, drug-eluting stents are the superior devices, and
othing is off-label any longer.
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